Vermillion Receives Notice of Allowance for Patent on Alzheimer's Biomarkers

The patent's claims cover biomarker combinations for the diagnosis and management of Alzheimer's disease and their measurement by methods including mass spectrometry and immunoassay.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.